Cargando…

A Meta-Analysis of Randomized Controlled Trials of Yiqi Yangyin Huoxue Method in Treating Diabetic Nephropathy

Objective. The purpose of this systematic review is to evaluate the evidence of Yiqi Yangyin Huoxue Method for diabetic nephropathy. Methods. 11 electronic databases, through September 2015, were searched to identify randomized controlled trials of Yiqi Yangyin Huoxue Method for diabetic nephropathy...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Jiao Ying, Huang, Di, Wu, Yan Sheng, Xu, Lin, He, Fei, Wang, Hui Ling, Shi, Li Qiang, Wan, Qiang, He, Li Qun, Dong Gao, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904113/
https://www.ncbi.nlm.nih.gov/pubmed/27313643
http://dx.doi.org/10.1155/2016/3257603
_version_ 1782437098565926912
author Ou, Jiao Ying
Huang, Di
Wu, Yan Sheng
Xu, Lin
He, Fei
Wang, Hui Ling
Shi, Li Qiang
Wan, Qiang
He, Li Qun
Dong Gao, Jian
author_facet Ou, Jiao Ying
Huang, Di
Wu, Yan Sheng
Xu, Lin
He, Fei
Wang, Hui Ling
Shi, Li Qiang
Wan, Qiang
He, Li Qun
Dong Gao, Jian
author_sort Ou, Jiao Ying
collection PubMed
description Objective. The purpose of this systematic review is to evaluate the evidence of Yiqi Yangyin Huoxue Method for diabetic nephropathy. Methods. 11 electronic databases, through September 2015, were searched to identify randomized controlled trials of Yiqi Yangyin Huoxue Method for diabetic nephropathy. The quality of the included trials was assessed using the Jadad scale. Results. 26 randomized controlled trials were included in our review. Of all the included trials, most of them were considered as high quality. The aggregated results suggested that Yiqi Yangyin Huoxue Method is beneficial to diabetic nephropathy in bringing down the microalbuminuria (SMD = −0.98, 95% CI −1.22 to −0.74), serum creatinine (SMD = −0.56, 95% CI −0.93 to −0.20), beta-2 microglobulin (MD = 0.06, 95% CI 0.01 to 0.12), fasting plasma glucose (MD = −0.35, 95% CI −0.62 to −0.08), and 2-hour postprandial blood glucose (MD = 1.13, 95% CI 0.07 to 2.20), but not in decreasing blood urea nitrogen (SMD = −0.72, 95% CI −1.47 to 0.02) or 2-hour postprandial blood glucose (SMD = −0.48, 95% CI −1.01 to 0.04). Conclusions. Yiqi Yangyin Huoxue Method should be a valid complementary and alternative therapy in the management of diabetic nephropathy, especially in improving UAER, serum creatinine, fasting blood glucose, and beta-2 microglobulin. However, more studies with long follow-up are warrant to confirm the current findings.
format Online
Article
Text
id pubmed-4904113
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-49041132016-06-16 A Meta-Analysis of Randomized Controlled Trials of Yiqi Yangyin Huoxue Method in Treating Diabetic Nephropathy Ou, Jiao Ying Huang, Di Wu, Yan Sheng Xu, Lin He, Fei Wang, Hui Ling Shi, Li Qiang Wan, Qiang He, Li Qun Dong Gao, Jian Evid Based Complement Alternat Med Research Article Objective. The purpose of this systematic review is to evaluate the evidence of Yiqi Yangyin Huoxue Method for diabetic nephropathy. Methods. 11 electronic databases, through September 2015, were searched to identify randomized controlled trials of Yiqi Yangyin Huoxue Method for diabetic nephropathy. The quality of the included trials was assessed using the Jadad scale. Results. 26 randomized controlled trials were included in our review. Of all the included trials, most of them were considered as high quality. The aggregated results suggested that Yiqi Yangyin Huoxue Method is beneficial to diabetic nephropathy in bringing down the microalbuminuria (SMD = −0.98, 95% CI −1.22 to −0.74), serum creatinine (SMD = −0.56, 95% CI −0.93 to −0.20), beta-2 microglobulin (MD = 0.06, 95% CI 0.01 to 0.12), fasting plasma glucose (MD = −0.35, 95% CI −0.62 to −0.08), and 2-hour postprandial blood glucose (MD = 1.13, 95% CI 0.07 to 2.20), but not in decreasing blood urea nitrogen (SMD = −0.72, 95% CI −1.47 to 0.02) or 2-hour postprandial blood glucose (SMD = −0.48, 95% CI −1.01 to 0.04). Conclusions. Yiqi Yangyin Huoxue Method should be a valid complementary and alternative therapy in the management of diabetic nephropathy, especially in improving UAER, serum creatinine, fasting blood glucose, and beta-2 microglobulin. However, more studies with long follow-up are warrant to confirm the current findings. Hindawi Publishing Corporation 2016 2016-05-30 /pmc/articles/PMC4904113/ /pubmed/27313643 http://dx.doi.org/10.1155/2016/3257603 Text en Copyright © 2016 Jiao Ying Ou et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ou, Jiao Ying
Huang, Di
Wu, Yan Sheng
Xu, Lin
He, Fei
Wang, Hui Ling
Shi, Li Qiang
Wan, Qiang
He, Li Qun
Dong Gao, Jian
A Meta-Analysis of Randomized Controlled Trials of Yiqi Yangyin Huoxue Method in Treating Diabetic Nephropathy
title A Meta-Analysis of Randomized Controlled Trials of Yiqi Yangyin Huoxue Method in Treating Diabetic Nephropathy
title_full A Meta-Analysis of Randomized Controlled Trials of Yiqi Yangyin Huoxue Method in Treating Diabetic Nephropathy
title_fullStr A Meta-Analysis of Randomized Controlled Trials of Yiqi Yangyin Huoxue Method in Treating Diabetic Nephropathy
title_full_unstemmed A Meta-Analysis of Randomized Controlled Trials of Yiqi Yangyin Huoxue Method in Treating Diabetic Nephropathy
title_short A Meta-Analysis of Randomized Controlled Trials of Yiqi Yangyin Huoxue Method in Treating Diabetic Nephropathy
title_sort meta-analysis of randomized controlled trials of yiqi yangyin huoxue method in treating diabetic nephropathy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904113/
https://www.ncbi.nlm.nih.gov/pubmed/27313643
http://dx.doi.org/10.1155/2016/3257603
work_keys_str_mv AT oujiaoying ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT huangdi ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT wuyansheng ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT xulin ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT hefei ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT wanghuiling ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT shiliqiang ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT wanqiang ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT heliqun ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT donggaojian ametaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT oujiaoying metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT huangdi metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT wuyansheng metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT xulin metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT hefei metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT wanghuiling metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT shiliqiang metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT wanqiang metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT heliqun metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy
AT donggaojian metaanalysisofrandomizedcontrolledtrialsofyiqiyangyinhuoxuemethodintreatingdiabeticnephropathy